<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with genetic polymorphisms of the CYP2D6 and the HO-1 GT allele make treatment and prognosis challenging. Carriers of these different polymorphisms will respond well to medications and have less risk of developing complications from COVID-19 such as ARDS and multiorgan failure, while others will develop toxic drug levels and multiorgan failure [
 <xref rid="B106-antioxidants-09-00636" ref-type="bibr">106</xref>] (
 <xref ref-type="fig" rid="antioxidants-09-00636-f004">Figure 4</xref>). This may explain the unpredictability clinicians are observing with COVID-19 patients and variable results regarding 4-aminoquinolones. More recent data suggests that 4-aminoquinolones showed no benefit over the standard of care and patients were at higher risk of developing cardiac arrest in the treatment group, especially when combined with Azithromycin [
 <xref rid="B117-antioxidants-09-00636" ref-type="bibr">117</xref>,
 <xref rid="B118-antioxidants-09-00636" ref-type="bibr">118</xref>].
</p>
